Certikova-Chabova, Vera ; Vernerova, Zdenka ; Kujal, Peter ; Huskova, Zdenka ; Skaroupkova, Petra ; Tesal, Vladimir ; Kramer, Hubert J. ; Kompanowska-Jezierska, Elżbieta ; Walkowska, Agnieszka ; Sadowski, Janusz ; Cervenka, Ludek ; Vaneckova, Ivana
Department of Nephrology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic ; artment of Renal and Body Fluid Physiology, M. Mossakowski Medical Research Centre, Polish Academy of Science, Warsaw, Poland of Institute of Physiology , Academy of Sciences of the Czech Republic, Prague
MS: There is evidence that in addition to hypertension and hyperactivity of the renin-angiotensin system (RAS), enhanced intrarenal activity of endothelin (ET) system contributes to the pathophysiology and progression of chronic kidney disease (CKD). This prompted us to examine if this progression would be alleviated by addition of type A ET receptor (ETA) blockade to the standard blockade of RAS.MAIN METHODS: Ren-2 transgenic rats (TGR) after 5/6 renal ablation (5/6 NX) served as a model of CKD. For RAS inhibition a combination of angiotensin-converting enzyme inhibitor (trandolapril, 6 mg/L drinking water) and angiotensin II type 1 receptor blocker (losartan, 100 mg/L drinking water) was used. Alternatively, ETA receptor blocker (atrasentan, 5 mg·kg(-1)·day(-1) in drinking water) was added to the combined RAS blockade. The follow-up period was 44 weeks after 5/6 NX, and the rats' survival rate, systolic blood pressure (SBP), proteinuria and indices of renal glomerular damage were evaluated.KEY FINDINGS: The survival rate was at first improved, by either therapeutic regime, however, the efficiency of RAS blockade alone considerably decreased 36 weeks after 5/6 NX: final survival rate of 65% was significantly lower than 91% achieved with combined RAS and ETA receptor blockade. SBP was not affected by the addition of ETA blockade while proteinuria and renal glomerular damage were further reduced.
Creative Commons Attribution BY-NC-SA 3.0 PL license
Copyright-protected material. [CC BY-NC-SA 3.0 PL] May be used within the scope specified in Creative Commons Attribution BY-NC-SA 3.0 PL license, full text available at: ; -
Mossakowski Medical Research Institute PAS
Library of the Mossakowski Medical Research Institute PAS
Programme Innovative Economy, 2010-2014, Priority Axis 2. R&D infrastructure
Mar 24, 2022
Dec 23, 2015
125
https://rcin.org.pl./publication/77983
Walkowska, Agnieszka Kuczeriszka, Marta Sadowski, Janusz Olszyński, Krzysztof Hubert Dobrowolski, Leszek Cervenka, Ludek Hammock, BD Kompanowska-Jezierska, Elżbieta
Certikova Chabova, Vera Walkowska, Agnieszka Kompanowska-Jezierska, Elżbieta Sadowski, Janusz Kujal, Peter Vernerova, Zdenka Vanourkova, Zdenka Kopkan, Libor Kramer, Herbert J Falck, John R Imig, John D Hammock, Bruce D Vaneckova, Ivana Cervenka, Ludek
Kuczeriszka, Marta Dobrowolski, Leszek Walkowska, Agnieszka Sadowski, Janusz Kompanowska-Jezierska, Elżbieta
Walkowska, Agnieszka Badzyńska, Bożena Kompanowska-Jezierska, Elżbieta Johns, EJ Sadowski, Janusz
Kompanowska-Jezierska, Elżbieta
Kompanowska-Jezierska, Elżbieta
Kompanowska-Jezierska, Elżbieta Kuczeriszka, Marta
Walkowska, Agnieszka